-

Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms

original Peter Seongwon Hong will serve as the Chief Executive Officer (CEO) of Epis NexLab, in addition to his current role as the Executive Vice President and Head of Research and Early Development at Samsung Bioepis.

Peter Seongwon Hong will serve as the Chief Executive Officer (CEO) of Epis NexLab, in addition to his current role as the Executive Vice President and Head of Research and Early Development at Samsung Bioepis.

INCHEON, Korea--(BUSINESS WIRE)--Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms.

Building on the R&D expertise accumulated through years of biosimilar development, we will focus on securing next-generation biotechnology platforms that can drive sustainable growth beyond the biosimilar business.

Share

Epis NexLab will focus on transforming highly scalable core technologies into platforms for the discovery of diverse new drug candidates, including license-out or joint development with global pharmaceutical companies. As part of its search for new business opportunities, the company plans to explore various new modalities including amino acid or peptide conjugate platform technologies.

Peter Seongwon Hong will serve as the Chief Executive Officer (CEO) of Epis NexLab, in addition to his current role as the Executive Vice President and Head of Research and Early Development at Samsung Bioepis. He will also serve on the board of directors of Samsung Epis Holdings as a non-executive director.

“Building on the R&D expertise accumulated through years of developing quality-assured biologics at Samsung Bioepis, we will focus on securing next-generation biotechnology platforms that can drive sustainable growth for the new company beyond the biosimilar business,” said Peter Seongwon Hong, CEO of Epis NexLab. “Our long-term goal is to become a leading biotechnology company in next-generation therapeutic technologies and we will be relentless in our efforts to drive this growth, through innovative research and development and strategic investment.”

Epis NexLab

Established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab will focus on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Samsung Epis Holdings and Epis NexLab, please visit: www.samsungepisholdings.com

Contacts

MEDIA CONTACT – Samsung Bioepis
Anna Nayun Kim, nayun86.kim@samsung.com
Yoon Kim, yoon1.kim@samsung.com

Industry:

Samsung Epis Holdings Co., Ltd.

Release Summary
Samsung Epis Holdings announced the establishment of Epis NexLab to advance the development of next-generation biotechnology platforms.
Release Versions
English
Hashtags
#EpisNexLab
#SamsungBioepis
#SamsungEpisHoldings
#biosimilars
#biotechnology
#peptides
#samsung

Contacts

MEDIA CONTACT – Samsung Bioepis
Anna Nayun Kim, nayun86.kim@samsung.com
Yoon Kim, yoon1.kim@samsung.com

More News From Samsung Epis Holdings Co., Ltd.

Samsung Bioepis Releases Third Quarter 2026 Biosimilar Market Report

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today released its Third Quarter 2026 Biosimilar Market Report, marking the fourteenth edition of the Quarterly Biosimilar Market Report in the United States (US). The report provides an overview of the market status of all biosimilars available in the US, including approval and launch status, pricing (both Average Sales Price, or ASP, and Wholesale Acquisition Cost, or WAC), and market uptake per molecule. The Deep Dive section in this...

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for commercialization of BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTIS1 (ranibizumab), and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEA2 (aflibercept), upon full transition of commercialization rights from Biogen back to Samsung Bioepis by the end of 20...

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and...
Back to Newsroom